EGFR and non-small cell lung carcinoma: The EGFR family are major contributors to complex signalling cascades that control cell growth, differentiation, migration, and survival.68 Mutations and aberrations in EGFR activity play an important role in many malignancies, including breast, lung, and oesophageal cancers, amongst others, making EGFR an attractive target for intervention.69,70 Gefitinib, first characterised in 1996, was the first EGFR inhibitor to be approved by the FDA, for the treatment of NSCLC, in 2003.